Glyza
Glyza Uses, Dosage, Side Effects, Mechanism of Action, How Long Does it Take to Work? Glyza is a brand name. Its generic name is Saxagliptin.
Introduction
Glyza is an oral antihyperglycemic (blood sugar-lowering) drug of the dipeptidyl peptidase-4 (DPP-4) inhibitor class, used for the treatment of type 2 diabetes mellitus. It helps to decrease the amount of glucose in the blood by inhibiting the enzyme that breaks down glucagon-like peptide-1 (GLP-1), a hormone that decreases blood sugar.Uses
Glyza is used to improve glycemic control in adults with type 2 diabetes mellitus with dietary modifications and physical activity. Glyza can also be used in combination with other antihyperglycemic agents, such as metformin or insulin, to further improve glycemic control.Mechanism of Action
Glyza works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for breaking down glucagon-like peptide-1 (GLP-1), a hormone that helps to decrease the amount of glucose in the blood. By inhibiting the breakdown of GLP-1, saxagliptin helps to keep blood sugar levels under control.How Long Does it Take to Work?
Glyza can take approximately 4 to 6 weeks to reach its full effect, since it needs time to be absorbed and metabolized.Absorption
Glyza is rapidly and completely absorbed from the gastrointestinal tract, with maximum plasma concentration reached in approximately 1 hour.Route of Elimination
Glyza is mainly eliminated in urine, with an estimated 41% to 51% of the dose being eliminated unchanged in urine.Dosage
Glyza is available as a 2.5 mg and 5 mg tablet. The recommended starting dose of saxagliptin is 2.5 mg orally once daily. This dose may be increased to 5 mg once daily if needed to further improve glycemic control.Administration
Glyza should be taken orally with or without food.Side Effects
Common side effects of saxagliptin include nasopharyngitis, upper respiratory tract infection, and headache. More serious side effects include anaphylaxis, angioedema, and acute pancreatitis.Toxicity
Glyza has no known toxic effects.Precautions
It is important to tell your doctor if you have kidney problems before taking saxagliptin. Additionally, it is also important to tell your doctor about any other medications you are taking before taking saxagliptin to prevent any drug interactions.Interactions
Glyza can interact with certain medications, such as ACE inhibitors (e.g. lisinopril) and thiazolidinediones (e.g. pioglitazone). Therefore, it is important to tell your doctor about any medications you are taking before using saxagliptin.Disease Interactions
Glyza should be used with caution in patients with kidney or liver problems.Drug Interactions
Glyza can interact with other medications, such as ACE inhibitors (e.g. lisinopril) and thiazolidinediones (e.g. pioglitazone). Therefore, it is important to tell your doctor about any medications you are taking before using saxagliptin.Food Interactions
Glyza is not affected by food or dietary intake, and can be taken with or without food.Pregnancy Use
Glyza should not be used during pregnancy.Lactation Use
It is unknown whether saxagliptin is excreted in human milk. Therefore, it is recommended to exercise caution when administering saxagliptin to women who are breastfeeding.Acute Overdose
No cases of saxagliptin overdose have been reported.Contraindication
Glyza should not be used in patients with a history of anaphylaxis or angioedema related to saxagliptin or any of its ingredients.Use Directions
Glyza should be taken as prescribed and should not be used at higher doses than those recommended.Storage Conditions
Glyza should be stored at room temperature, away from moisture and heat.Volume of Distribution
The estimated volume of distribution of saxagliptin is 24.4 L.Half Life
The estimated half-life of saxagliptin is 7.5 hours.Clearance
The estimated clearance of saxagliptin is 55.2 mL/min.Here you find in details version of Glyza
Some Frequently Asked Questions About Glyza
https://www.medicinesfaq.com/brand/glyza,
,
,
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:71272,
http://www.hmdb.ca/metabolites/HMDB0015634,
http://www.genome.jp/dbget-bin/www_bget?drug:D08996,
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11243969,
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=99443245,
https://www.chemspider.com/Chemical-Structure.9419005.html,
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50225074,
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1546030,
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=71272,
https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL385517,
http://www.pharmgkb.org/drug/PA165958362,
http://www.rxlist.com/onglyza-drug.htm,
https://www.drugs.com/international/saxagliptin.html,
https://en.wikipedia.org/wiki/Saxagliptin,